Nevirapine Viatris

Nevirapine, the active ingredient in Nevirapine Viatris, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of HIV‑1 infection in adults and adolescents, typically as part of a combination antiretroviral regimen.

GNH USA supplies Nevirapine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand, including temperature‑controlled logistics where required throughout.

Nevirapine Viatris is used to manage HIV‑1 infection, a viral disease treated by targeting reverse transcriptase activity. - HIV‑1 infection (adult): Reduces plasma viral load and improves immune function when combined with other antiretrovirals. - HIV‑1 infection (pediatric): Provides viral suppression in children as part of a recommended combination regimen. - Treatment‑experienced HIV‑1 infection: Offers an alternative option for patients with resistance to other NNRTIs.

Nevirapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions that may appear early in therapy. - Nausea: transient gastrointestinal discomfort often resolving with continued use. - Fatigue: generalized tiredness reported by some patients. - Headache: mild to moderate intensity, usually self‑limiting. - Dizziness: occasional sensation of light‑headedness. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver toxicity such as jaundice or elevated enzymes. - Severe hypersensitivity: systemic allergic response with fever and rash. - Neutropenia: marked reduction in white blood cells increasing infection risk. - Liver toxicity: serious hepatic injury manifesting as hepatitis. - Life‑threatening skin reactions: including toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient history and monitor for specific risks. - Liver function monitoring: obtain baseline tests and repeat periodically during treatment. - Pregnancy considerations: use only if benefits outweigh potential risks; category B. - Concomitant hepatitis B or C: evaluate liver status closely. - Drug resistance testing: perform before starting to ensure susceptibility. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture and light.

Nevirapine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may increase nevirapine concentrations and risk toxicity. - St. John's wort: can reduce nevirapine exposure, compromising antiviral effect. - Efavirenz: combined use may heighten hepatotoxic risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may raise nevirapine levels modestly. - Macrolide antibiotics (e.g., erythromycin): can affect metabolism. - Oral contraceptives: nevirapine may reduce hormonal efficacy, requiring additional contraception.